Lilly reports 20.9% weight loss at the 12 mg dose over 80 weeks versus 9.4% on Ozempic, and plans to seek US approval next year.
Recap by typeshit. Full story at https://www.irishsun.com/.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
TM Smith, D.O. shares results from the open-label study of 1,298 adults with type 2 diabetes, run over 80 weeks.
Mgoes highlights the figures, including up to 30% at two years in the extension. The drug is still in phase 3 and not approved.
Loading…